SoheilMeshinchiMDPhD

PubMed

• Long-read epigenomic diagnosis and prognosis of Acute Myeloid Leukemia.
  Jatinder Lamba, Francisco Marchi, Marieke Landwehr, Ann-Kathrin Schade, Vivek Shastri
  Research Square. 2024-12-12
• Influence of Nucleophosmin () Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration.
  Claudia Tregnago, Maddalena Benetton, Rhonda E Ries, Jack H Peplinski, Todd A Alonzo
  Journal of Clinical Oncology. 2024-12-02
• Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report.
  Jasmine Naru, Megan Othus, ChenWei Lin, Melinda A Biernacki, Marie Bleakley
  Ejhaem. 2024-12-01

Journal Articles

• Acute Myeloid Leukemia in Children and Adolescents: Identification of New Molecular Targets Brings Promise of New Therapies  
  Soheil Meshinchi, MD, Hematology ASH Education Program
• Prognostic Impact of T(16;21)(p11;q22) and T(16;21)(q24;q22) in Pediatric AML: A Retrospective Study by the I-BFM Study Group  
  Soheil Meshinchi, Tanja A Gruber, Blood
• Pan-cancer Genome and Transcriptome Analyses of 1,699 Pediatric Leukemias and Solid Tumors  
  Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pou..., Nature Medicine, 1/1/2018
• MicroRNA Expression-based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia  
  Lim EL, Trinh DL, Ries RE, Wang J, Gerbing RB, Ma Y, Topham J, Hughes M, Pleasance E, Mungall AJ, Moore R, Zhao Y, Aplenc R, Sung L, Kolb EA, Gamis A, Smith M, Gerhard..., Journal of Clinical Oncology, 1/1/2017
• Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia  
  Paguirigan AL, Smith J, Meshinchi S, Carroll M, Maley C, Radich JP, Sci Transl Med, 1/1/2015
• Prognostic Significance of NPM1 Mutations in the Absence of FLT3-Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Canc...  
  Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogosova-Agadjan..., J Clin Oncol, 1/1/2015
• Sample processing obscures cancer-specific alterations in leukemic transcriptomes  
  Dvinge H, Ries RE, Ilagan JO, Stirewalt DL, Meshinchi S, Bradley RK, Proc Natl Acad Sci USA, 1/1/2014
• BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncolo...  
  Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Pediatr Blood Cancer, 1/1/2014
• High Expression of Suppressor of Cytokine Signaling-2 Predicts Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group  
  Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB, Leuk Lymphoma, 1/1/2014
• Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML  
  Stirewalt D, Pogosova-Agadjanyan E, Tsuchiya K, Joaquin J, Meshinchi S, Blood Cancer, 1/1/2014
• Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncolog...  
  Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS, Meshinchi S, Br J Haematol, 1/1/2014
• Co-expression of NUP98/NSD1 and FLT3/ITD in Acute Myeloid Leukemia leads to High-Risk of Induction Failure: a COG and SWOG Report  
  Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S, Blood, 1/1/2014
• Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomize...  
  Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Daviec R, J Clin Oncol, 1/1/2014
• Outlier Analysis and Top Scoring Pair for Integrated Data Analysis and Biomarker Discovery  
  Ochs MF, Farrar JE, Considine M, Wei Y, Meshinchi S, Arceci RJ, IEEE/ACM Trans Comput Biol Bioinform, 1/22/2013
• A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positively in patients with newly diagnosed acute myeloid leukemia  
  Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, Lis..., Br J Haematol, 1/1/2013
• Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Contai...  
  Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J, Pounds S, Cao X, Rubnitz JE, Ribeiro RC, Gamis A, Meshi..., Clin Cancer Res, 1/1/2013
• Significance of Expression of ITGA5 and its Splice Variants in Acute Myeloid Leukemia: A Report from the Children's Oncology Group  
  Walter RB, Laszlo GS, Alonzo TA, Gerbing RB, Levy S, Fitzgibbon MP, Gudgeon CJ, Ries RE, Harrington KH, Raimondi SC, Hirsch BA, Gamis AS, McIntosh MW, Meshinchi S, Am J Hematol, 1/1/2013
• High EVI1 Expression Is Associated with MLL Rearrangements and Predicts Decreased Survival in Paediatric AML: A Report From the Children's Oncology Group  
  Ho PA, Alonzo TA, Gerbing RB, Pollard JA, Hirsch B, Raimondi SC, Cooper T, Gamis AS, Meshinchi S, Br J Haematol, 1/1/2013
• Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients  
  Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB, Lange BJ, Meshinchi S, Woods WG, Perentesis J, Horan J, Cancer, 1/1/2013
• Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Onco...  
  Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S, Blood, 1/1/2012
• Stimulation of fibroblast proliferation by insoluble gadolinium salts  
  Bleavins K, Perone P, Naik M, Rehman M, Aslam MN, Dame MK, Meshinchi S, Bhagavathula N, Varani J, Biol Trace Elem Res, 1/1/2012
• Lessons Learned From the Investigational Device Exemption (IDE) Review of Children's Oncology Group Trial AAML1031  
  Meshinchi S, Hunger SP, Aplenc R, Adamson PC, Jessup JM, Clinical Cancer Research, 1/1/2012
• Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML  
  Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB, Gamis A, Meshinchi S, Blood, 1/1/2012
• FLT3 Mutations are Prevalent and are Significantly Associated with Induction Death in Pediatric Acute Promyelocytic Leukemia, a Report from the Children's Oncology Group  
  Kutny MA, Moser BK, Gregory J, Woods WG, Feusner JH, Meshinchi S, Pediatric Blood and Cancer, 1/1/2012
• Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG  
  Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Ander..., Blood, 1/1/2011
• Join now to see all

Books/Book Chapters

• Principles and Practice of Pediatric Oncology 
  Chapter: "Acute Myeloid Leukemia and Myelodysplastic Syndromes" 
  Arceci RJ, Meshinchi SEditors: Pizzo P, and Poplack D.Wolters Kluwer, PhiladelphiaEdition 7th,2015
• Molecular Oncology: Causes of Cancer and Targets for Treatment 
  Chapter: "FMS-related tyrosine kinase 3." 
  Page 144 - 161Meshinchi S and Stirewalt DLEditors: "FMS-related tyrosine kinase 3".2014
• Hematopoietic Cell Transplantation in Children with Cancer 
  Chapter: "Acute Myeloid Leukemia" 
  Horan J, Hasle H, Meshinchi SEditors: Smith FO, Reaman GH, and Racadio JM.Springer, Heidelberg2014
• Cancer Genomics: From Bench to Personalized Medicine 
  Chapter: "Acute Myeloid Leukemia" 
  Arceci RJ, Berman JN, Meshinchi SEditors: Dellaire G, Berman JN, and Arceci RJ.Academic, Amsterdam2014
• Hematological Malignancies in Children, Adolescents and Young Adults 
  Chapter: "Molecular Genetics in Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia" 
  Page 121 - 142Mullighan CG, Hunger SP, Meshinchi SEditors: Cairo MS, Perkins S.World Scientific, Singapore2012
• Hematological Malignancies in Children, Adolescents and Young Adults 
  Chapter: "Childhood, Adolescent and Young Adult (CAYA) Acute Myeloid Leukemias" 
  Page 237 - 266Arceci RJ, Meshinchi S, Rosenblat TL, Jurcic JG, Tallman MSEditors: Cairo MS, Perkins S.World Scientific, Singapore2012
• Rudolph's Pediatrics 
  Chapter: "Myeloid Malignancies" 
  Meshinchi S, Weinstein HJ, Arceci RJEditors: Rudolph AM, Rudolph C, First L, Lister G, Gershon AA.Edition 22nd,2011
• Childhood Leukemia 
  Chapter: "Biology of Acute Myeloid Leukemia" 
  Page 63 - 76Arceci RJ, Meshinchi SEditors: Reaman GH, Smith FO.2011
• Acute Myelogenous Leukemia: Genetics, Biology and Therapy 
  Chapter: "Receptor Tyrosine Kinase Alterations in AML - Biology and Therapy" 
  Page 85 - 108Stirewalt DL and Meshinchi SEditors: ST Rosen.2009
• Molecular Oncology: Causes of Cancer and Targets for Treatment 
  Chapter: "Tyrosine kinase alterations in AML" 
  Stirewalt DL and Meshinchi SEditors: E. Gelmann, C. Sawyers, and F. Rauscher III.Cambridge University Press, New York2008
• Towards Subgroup-directed Therapy in Acute Myeloid Leukemia 
  Chapter: "FLT3 Internal Tandem Duplication in childhood acute myeloid leukemia (AML): prognostic significance and relation to cellular drug resistance." 
  Page 101 - 115Zwaan CM, Meshinchi S, Radich JP, Veerman AJP, Huismans DR, Munske L, Podleschny M, Hahlen K , Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJL, Griesinger FKrips, Meppel, Netherlands2003
• The Steroid/Thyroid Hormone Receptor Family and Gene Regulation 
  Chapter: "Speculations on the role of the 90-kDa heat shock protein in glucocorticoid receptor transport and function." 
  Page 109 - 126Pratt WB, Redmond T, Sanchez ER, Bresnick EH, Meshinchi S, Welsh MJEditors: J. Carlstedt-Duke, H. Erickson, JA Gustafsson.Birkhauser-Verlag, Basel1989
• Sterol/Steroid Hormone Action 
  Chapter: "Inhibition of glucocorticoid receptor conversion to the DNA-binding state and inhibition of subunit dissociation." 
  Page 195 - 2011Sanchez ER, Tienrungroj W, Meshinchi S, Bresnick EH, Pratt WBEditors: T. Spelsberg and R. Kumar.Martinus Nijhoff1987
• Join now to see all

Abstracts/Posters

• In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational Profile
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous...
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the ChildrenÍs Oncology Group
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long Non-Coding RNAs (lncRNAs) Are Highly Associated with Disease Characteristics and Outcome in Pediatric Acute Myeloid Leukemia _ a COG and Tpaml Study
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Transcriptome Profiling of Pediatric Myeloproliferative Neoplasms Demonstrates Dysregulation of Platelet-Relevant Genes and Enrichment of Inflammatory and JAK2 Mediate...
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparison of Outcomes between HSCT Donor Sources for Pediatric Patients with Hematologic Malignancies
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeu...
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia
  Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene _ a COG/Tpaml Study
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Transcriptome Analysis of Pediatric AML Reveals Non Protein-Coding RNAs Associated with Poor Survival Outcome and Treatment Resistance
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CBFA2T3-GLIS2 induces Malignant Transformation of Primitive CD34+ Cord Blood Cells and Recapitulates Infant Megakaryocytic Leukemia
  Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The LSC17 Leukemic Stem Cell Signature Predicts Outcome in Pediatric Acute Myeloid Leukemia.
  Smith JL, Ries RE, Kolb EA, Alonzo TA, Gerbing RB, Ma Y, Marra MA, Bolouri H, Meshinchi S, ASH (American Society of Hematology) Annual Meeting Abstracts, 1/1/2017
• Functional Properties of Exon 17 KIT Mutations in Pediatric CBF AML Predict for Inferior Outcome and Enhanced Response to Tyrosine Kinase Inhibition: A Report from the...
  Tarlock K, Alonzo TA, Gerbing RB, Wang Y-C, Ries RE, Hylkema T, Joaquin J, Raimondi SC, Hirsch BA, Kolb EA, Gamis AS, Meshinchi S, Pollard JA, ASH (American Society of Hematology) Annual Meeting Abstracts, 1/1/2017
• Evaluation of Cancer Testis Antigens (CTAs) As Immuno-Therapeutic Targets in Pediatric AM.
  Ries RE, Smith JL, Triche T, Farrar JE, Alonzo TA, Ma Y, Wei L, Guidry Auvil J, Gerhard DS, Marra MA, Gamis AS, Kolb EA, Bolouri H, Meshinchi S, ASH (American Society of Hematology) Annual Meeting Abstracts, 1/1/2017
• Join now to see all

Lectures

• ABCB1 rs1045642 C>T Change Is Associated with AML Cell Line Sensitivity to Calicheamicin 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Signaling Responses to Stroma-Derived Soluble Factors Are Associated with Outcome and with Expression of Microenvironment-Related Genes in Pediatric AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Integrating New Molecular Targets in Acute Leukemias and Myeloproliferative Neoplasms 
  Dallas, TX - 1/1/2018
• "New Risk Stratified in Pediatric AML" 
  1/30/2017
• A Perspective on Genomics in Clinical Practice: Focus on Pediatric Cancers 
  1/28/2017
• Defining biology of genomic alterations in AML. 
  1/27/2017
• "Genome and Epigenome of AML in Children and Young Adults" 
  1/17/2017
• "AML: Evolving Landscape" 
  1/7/2017
• Genome and Epigenome of AML in Children and Young Adults 
  1/1/2017
• "FLT3 Mutations and Mutational Spectrum in AML" 
  Madrid, Spain - 1/1/2017
• Biologic basis of FLT3 mutations in AML 
  St. Louis, MO - 1/1/2016
• "The TARGET Project (Therapeutically Applicable Research to Generate Effective Treatments)" 
  St. Louis, MO - 1/24/2015
• "Targeting Genomic Alterations in AML" 
  Children's Hospital Colorado, Denver, CO - 1/14/2014
• "Biomarkers for Risk-Based Therapy in AML" 
  Chicago, IL - 1/13/2014
• "TARGET AML Initiative - Genomic Landscape in Childhood AML" 
  Bethesda, MD - 1/9/2014
• "Evolving AML Genome" 
  Seattle, WA - 1/4/2014
• "Defining Genomic Landscape in Childhood AML-Implications for Clinical Intervention" 
  Children's Hospital of Michigan, Detroit, MI - 1/3/2014
• "Genomic Landscape in Childhood AML" 
  Alfred I. duPont Hospital for Children, Wilmington, DE - 1/21/2013
• NCI/ASCO/FDA initiative for use of minimal residual disease as a surrogate end point for response assessment in AML. 
  Bethesda, MD - 1/4/2013
• "Genomic and Epigenomic Alterations in AML" 
  Seattle, WA - 1/4/2013
• "Identification of Novel Therapeutic Targets for Childhood Cancers" 
  Washington, DC - 1/1/2013
• "The NCI Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative: Using Large-Scale Genomics to Identify Novel Therapeutic Targets for... 
  Chicago, IL - 1/1/2012
• NCI Cancer Genomics 
  Bethesda, MD - 1/1/2012
• Join now to see all